Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28538435 | 0.84 | — | — | |
| SCHEMBL28003639 | 0.83 | TDP1 (0.67) | TDP1KDM4EALDH1A1GLAGAA | |
| SCHEMBL28067241 | 0.83 | CYP1A1 (0.50) | LDHA | |
| SCHEMBL9748786 | 0.82 | CYP1A2 (0.54) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL30238199 | 0.81 | KDM4E (0.69) | TDP1KDM4EALDH1A1GLAGAA | |
| SCHEMBL9682990 | 0.81 | KDM4E (0.69) | TDP1KDM4EALDH1A1GLAGAA | |
| Hydrochloric Acid SCHEMBL8440785 | 0.81 | TDP1 (0.96) | TDP1KDM4EALDH1A1GLAGAA | |
| SCHEMBL27926016 | 0.81 | CYP1A2 (0.60) | TDP1KDM4EALDH1A1LDHA | |
| SCHEMBL11478267 | 0.80 | TDP1 (0.62) | TDP1KDM4EALDH1A1GLAGAA | |
| SCHEMBL7468694 | 0.80 | TDP1 (0.62) | TDP1KDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4333877-A | Substituted 2,7-dioxo-2,7-dihydrobenzo[1:2-b; 5:6-b1 ]difuran or -dipyrrole dyestuffs, their preparation and their use | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-06-08 | — | — | US | claimed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | disclosed |
| EP-1265849-B1 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7119085-B2 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-7030239-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-6992081-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| US-6737420-B2 | A SUBSTITUTED HYDROXYETHYLENE COMPOUND USEFUL FOR TREATING ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, DOWN'S SYNDROME, HEREDIATARY CEREBRAL HEMMORRHAGE WITH AMYLOIDOSIS, DEGENERATIVE DEMENTIA | ELAN PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | disclosed |
| US-20020019403-A1 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | PSEN1, PSEN2, BACE1 | TDP1 570/4885KDM4E 1510/4885ALDH1A1 165/4885 |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BCHE | TDP1 1331/4885KDM4E 1290/4885ALDH1A1 311/4885 |
| US-20020019403-A1 | Methods to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | TDP1 707/4885KDM4E 1730/4885ALDH1A1 214/4885 |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | TDP1 4792/4885KDM4E 1854/4885ALDH1A1 1527/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | TDP1 1064/4885KDM4E 1028/4885ALDH1A1 790/4885 |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BACE1 | TDP1 589/4885KDM4E 1179/4885ALDH1A1 463/4885 |
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | PSEN2, PSEN1, ACHE | TDP1 1429/4885KDM4E 1658/4885ALDH1A1 412/4885 |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | TDP1 2491/4885KDM4E 2319/4885ALDH1A1 1663/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | TDP1 570/4885KDM4E 1510/4885ALDH1A1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.